文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

淋巴结阳性宫颈癌患者接受当代放化疗及剂量递增治疗后的复发模式:一项多机构研究

Patterns of Recurrence in Node-Positive Cervical Cancer Patients Treated With Contemporary Chemoradiation and Dose Escalation: A Multi-Institutional Study.
PubMed 文献 · Pract Radiat Oncol · 2018-10-17

这项多机构回顾性研究纳入2004至2011年间接受根治性放化疗的78例淋巴结阳性宫颈癌患者,评估选择性扩大野放疗(EFRT)和淋巴结剂量递增对局部区域控制及生存的影响。结果显示3年总生存率为65%、无病生存率为50%,多数失败为远处转移;较高的淋巴结处方剂量和选择性EFRT均未影响DFS或OS。

要点

  • 盆腔淋巴结阳性与腹主动脉旁淋巴结(PALN)阳性患者的OS或DFS无显著差异(log-rank P=.24)。
  • 较高的淋巴结处方剂量(范围45-60 Gy)和选择性EFRT均未影响DFS或OS(Cox比例风险P>.05)。
  • 淋巴结剂量每增加1 Gy,区域复发风险有下降趋势(风险比0.85,Cox比例风险P=.08)。

核心结论

  • PALN受累患者的生存与仅盆腔淋巴结阳性患者相似。
  • 较高的淋巴结剂量可能改善区域控制但未影响生存。
  • 选择性扩大野放疗未影响本队列的结局。
  • 多数失败为远处转移,强调全身治疗可能的作用。

研究设计与样本

  • 在2个学术机构对2004年至2011年间接受根治性放化疗的盆腔和/或腹主动脉旁淋巴结转移宫颈癌患者进行回顾性综述。
  • 共纳入78例患者,记录失败模式,评估肿瘤和治疗对生存或复发的影响。
  • 存活患者的中位随访时间为34个月。

主要发现

  • 全部患者的3年总生存率为65%、无病生存率为50%。
  • 盆腔淋巴结阳性患者的3年OS为68%、DFS为52%;PALN阳性患者的3年OS为59%、DFS为48%。
  • 仅盆腔淋巴结阳性与PALN阳性患者的OS或DFS无显著差异(log-rank P=.24)。
  • 复发部位包括远处(n=22)、PALN(n=6)、中央盆腔(n=5)、盆腔淋巴结(n=3)和悬吊卵巢(n=1)。
  • 较高的淋巴结处方剂量(范围45-60 Gy)和选择性EFRT均未影响DFS或OS(Cox比例风险P>.05);淋巴结剂量每增加1 Gy,区域复发风险有下降趋势(风险比0.85,Cox比例风险P=.08);选择性EFRT未影响PALN失败率、OS或DFS(Cox比例风险P>.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the effect of elective extended field radiation (EFRT) and nodal dose escalation on locoregional control and survival in patients with node-positive cervical cancer treated with definitive chemoradiation at 2 academic institutions. METHODS AND MATERIALS: Patients with cervical cancer with pelvic and/or paraortic lymph node (PALN) metastases treated with definitive chemoradiation between 2004 and 2011 were retrospectively reviewed. Patterns of failure were recorded. The impact of tumor and treatment on survival or recurrence were evaluated. RESULTS: A total of 78 patients were included. Median follow-up in surviving patients was 34 months. The 3-year overall survival (OS) and disease-free survival (DFS) were 65% and 50%, respectively (all patients), 68% and 52% (pelvic lymph nodes), and 59% and 48% (PALN). OS or DFS in pelvic-only versus PALN-positive patients was not significantly different (log-rank P = .24). Recurrences were distant (n = 22), PALN (n = 6), central pelvis (n = 5), pelvic lymph node (n = 3), and suspended ovary (n = 1). Higher nodal prescribed dose (range, 45-60 Gy) and elective EFRT did not affect DFS or OS (Cox proportional hazards P > .05). There was a trend toward decreased regional recurrence with higher nodal dose (hazard ratio, 0.85 per Gy increase; Cox proportional hazards P = .08). Elective EFRT did not affect PALN failure rate, OS, or DFS (Cox proportional hazards P > .05). CONCLUSIONS: Survival of patients with PALN involvement was similar to those with pelvic-only nodes. Higher nodal dose may improve regional control but did not affect survival. Elective extended-field radiation did not affect outcomes in this cohort. Most failures were distant, emphasizing the potential role of systemic therapy to improve outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sethi R, Mayadev J, Sethi S, et al. Patterns of Recurrence in Node-Positive Cervical Cancer Patients Treated With Contemporary Chemoradiation and Dose Escalation: A Multi-Institutional Study. Pract Radiat Oncol. 2018. PMID: 30342181. doi:10.1016/j.prro.2018.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。